09/18/23 7:00 AMNasdaq : TNGX clinical trialTango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsTango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that five abstracts have been selected for poster presentations atRHEA-AIneutral
09/06/23 7:00 AMNasdaq : TNGX clinical trialTango Therapeutics Announces FDA Clearance of Investigational New Drug Application for TNG348, a Novel USP1 Inhibitor for the Treatment of BRCA1/2-mutant and Other HRD+ CancersTango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that the U.S. Food and Drug Administration (FDA) has cleared theRHEA-AIneutral
09/05/23 7:00 AMNasdaq : TNGX conferencesTango Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment ConferenceTango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that Barbara Weber, M.D., President and Chief Executive Officer ofRHEA-AIneutral
08/29/23 5:08 PMNasdaq : TNGX managementTango Therapeutics Announces Updates to Its Board of DirectorsTango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced changes to its Board of Directors. John Ketchum has been appointedRHEA-AIneutral
08/10/23 7:00 AMNasdaq : TNGX Tango Therapeutics Announces $80 million Private Placement FinancingTango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, has agreed to sell approximately 15.5 million shares of its common stock (“CommonRHEA-AIneutral
08/07/23 7:00 AMNasdaq : TNGX earningsTango Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Highlights– First patient dosed in phase 1/2 trial of TNG462, a next-generation PRMT5 inhibitor for the treatment of MTAP-deleted tumors – – Dose escalation ongoing in phase 1/2 trial of TNG908, a novel brain-penetrant PRMT5 inhibitor for the treatment of MTAP-deleted tumors – –First patient dosed in phaseRHEA-AIneutral
07/24/23 7:00 AMNasdaq : TNGX clinical trialTango Therapeutics Announces First Patient Dosed in TNG260 Phase 1/2 Trial in Patients With STK11-Mutant CancersTango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that the first patient has been dosed in the phase 1/2 trialRHEA-AIneutral
07/10/23 7:00 AMNasdaq : TNGX clinical trialTango Therapeutics Announces First Patient Dosed in TNG462 Phase 1/2 Trial in Patients With MTAP-deleted Solid TumorsTango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering the next generation of precision cancer medicines, today announced that the first patient has been dosed in the phase 1/2 trial of TNG462 in patientsRHEA-AIneutral
06/01/23 7:00 AMNasdaq : TNGX conferencesTango Therapeutics to Participate in Upcoming Investor ConferencesTango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that members of the management team are scheduled to participate inRHEA-AIneutral
05/09/23 7:00 AMNasdaq : TNGX earningsTango Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Highlights– Dose escalation update from ongoing TNG908 clinical trial confirms proof-of-mechanism for MTA-cooperative tumor-selective PRMT5 inhibition in MTAP-deleted cancers – – FDA clears IND application for TNG260, a first-in-class CoREST complex inhibitor for the treatment of STK11-mutant cancers – –RHEA-AIneutral